“十五五” 启新程 吉林敖东以全链匠心守护鹿茸瑰宝 安神补脑液持续领跑市场

Group 1 - The company adheres to the strategy of "dual-driven by pharmaceutical health and financial capital," focusing on the full industrial chain of deer antler and core product innovation to revitalize its traditional Chinese medicine brand [1] - The company has invested over 46 million yuan in upgrading epidemic prevention facilities, ensuring a zero-positive record for brucellosis and tuberculosis since 2021, thus maintaining a closed-loop management of deer antler raw materials [1] Group 2 - The company’s core product, the Anshen Bnnao Liquid, has sold nearly 10 billion units and generated annual revenue exceeding 700 million yuan, capturing over 70% of the national market share in its category [2] - The company plans to increase R&D investment during the 14th Five-Year Plan, focusing on the core material research of deer antler and advancing into the fields of anti-aging and regenerative medicine [2] Group 3 - The company emphasizes that its full industrial chain layout serves as both a quality "moat" and a stabilizer against cost fluctuations, while also fulfilling social responsibilities [3] - The company has implemented cash dividends for 18 consecutive years, totaling 4.739 billion yuan, reinforcing its commitment to long-term value growth [3]